EGFR and non-small cell lung carcinoma: These drugs have shown significant clinical benefits in patients with advanced NSCLC harboring Ex19del and L858R mutations.2,3 Although initial EGFR TKI therapy provides good disease control, acquired resistance is pervasive and remains a major obstacle.4